The mutation frequency of MYD88, CD79B, and PIM1 in PCNSLs is much higher than that of systemic DLBCL (67%, 63%, 70% versus 17%, 11%, 26%) [2,22]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.